Acorda Therapeutics announced that Inbrija levodopa inhalation powder has been launched in Germany by Esteve Pharmaceuticals. The EMA approved Inbrija DPI for the treatment of OFF periods in Parkinson’s disease in 2019. Acorda said that Esteve will pay “a significant double-digit percent of the selling price” plus sales based milestone payments.
In July 2021, Acorda announced that Esteve had acquired rights to distribute Inbrija in Spain and expected to launch the product in that country by the end of 2022. According to the current announcement, the launch in Spain is now expected in early 2023. Acorda also recently announced that Biopas Laboratories has acquired rights to Inbrija in nine Latin American countries, including Brazil and Mexico.
Acorda Chief Commercial Officer Kerry Clem said, “We are excited that Inbrija is now available to the people with Parkinson’s in Germany who may benefit from a new treatment to address their OFF periods. Esteve has a significant presence in Europe and an excellent track record of successfully commercializing neurological products there.”
The FDA approved Inbrija in December 2018, and Acorda launched the DPI in the US several months later. Catalent purchased the Inbrija manufacturing facility from Acorda in January 2021.
Read the Acorda press release.
